Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The study objective is to assess the efficacy and safety of cenegermin (rhNGF) ophthalmic solution at 20 mcg/mL concentration administered three times daily for 4 weeks in patients with severe Sjogren\'s dry eye disease (DED) who are under chronic treatment with topical Cyclosporine A (CsA).
Epistemonikos ID: 8d532a9a3ec1a17933c6bad3309704933c9aa8b0
First added on: May 09, 2024